Literature DB >> 19702573

Cross currents in protein misfolding disorders: interactions and therapy.

Rodrigo Morales1, Kristi M Green, Claudio Soto.   

Abstract

Protein Misfolding Disorders (PMDs) are a group of diseases characterized by the accumulation of abnormally folded proteins. Despite the wide range of proteins and tissues involved, PMDs share similar molecular and pathogenic mechanisms. Several epidemiological, clinical and experimental reports have described the co-existence of PMDs, suggesting a possible cross-talk between them. A better knowledge of the molecular basis of PMDs could have important implications for understanding the mechanism by which these diseases appear and progress and ultimately to develop novel strategies for treatment. Due to their similar molecular mechanisms, common therapeutic strategies could be applied for the diseases in this group.

Entities:  

Mesh:

Year:  2009        PMID: 19702573      PMCID: PMC2804467          DOI: 10.2174/187152709789541998

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  99 in total

1.  Early-onset familial Alzheimer disease with coexisting beta-amyloid and prion pathology.

Authors:  G Leuba; K Saini; A Savioz; Y Charnay
Journal:  JAMA       Date:  2000-04-05       Impact factor: 56.272

2.  Prion protein expression in senile plaques in Alzheimer's disease.

Authors:  I Ferrer; R Blanco; M Carmona; B Puig; R Ribera; M J Rey; T Ribalta
Journal:  Acta Neuropathol       Date:  2001-01       Impact factor: 17.088

Review 3.  Protein misfolding and disease; protein refolding and therapy.

Authors:  C Soto
Journal:  FEBS Lett       Date:  2001-06-08       Impact factor: 4.124

4.  Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.

Authors:  Eliezer Masliah; Edward Rockenstein; Anthony Adame; Michael Alford; Leslie Crews; Makoto Hashimoto; Peter Seubert; Michael Lee; Jason Goldstein; Tamie Chilcote; Dora Games; Dale Schenk
Journal:  Neuron       Date:  2005-06-16       Impact factor: 17.173

5.  Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.

Authors:  J Lewis; D W Dickson; W L Lin; L Chisholm; A Corral; G Jones; S H Yen; N Sahara; L Skipper; D Yager; C Eckman; J Hardy; M Hutton; E McGowan
Journal:  Science       Date:  2001-08-24       Impact factor: 47.728

Review 6.  Species barriers in prion diseases--brief review.

Authors:  R A Moore; I Vorberg; S A Priola
Journal:  Arch Virol Suppl       Date:  2005

Review 7.  Prion diseases of humans and animals: their causes and molecular basis.

Authors:  J Collinge
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

8.  Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice.

Authors:  K Hsiao; P Chapman; S Nilsen; C Eckman; Y Harigaya; S Younkin; F Yang; G Cole
Journal:  Science       Date:  1996-10-04       Impact factor: 47.728

9.  Coexistence of Alzheimer-type neuropathology in Creutzfeldt-Jakob disease.

Authors:  J A Hainfellner; J Wanschitz; K Jellinger; P P Liberski; F Gullotta; H Budka
Journal:  Acta Neuropathol       Date:  1998-08       Impact factor: 17.088

10.  Therapeutic strategies against protein misfolding in neurodegenerative diseases.

Authors:  Claudio Soto; Zane Martin
Journal:  Expert Opin Drug Discov       Date:  2008-12-10       Impact factor: 6.098

View more
  25 in total

1.  Evidence of a Prion-Like Transmission of p53 Amyloid in Saccharomyces cerevisiae.

Authors:  Shinjinee Sengupta; Samir K Maji; Santanu K Ghosh
Journal:  Mol Cell Biol       Date:  2017-08-28       Impact factor: 4.272

Review 2.  The neuropathology of chronic traumatic encephalopathy.

Authors:  Ann C McKee; Thor D Stein; Patrick T Kiernan; Victor E Alvarez
Journal:  Brain Pathol       Date:  2015-05       Impact factor: 6.508

3.  Longitudinal study of experimental induction of AA amyloidosis in mice seeded with homologous and heterologous AA fibrils.

Authors:  Naeem Muhammad; Tomoaki Murakami; Yasuo Inoshima; Naotaka Ishiguro
Journal:  Inflamm Res       Date:  2016-05-10       Impact factor: 4.575

4.  Long-term kinetics of AA amyloidosis and effects of inflammatory restimulation after disappearance of amyloid depositions in mice.

Authors:  N Muhammad; T Murakami; Y Inoshima; N Ishiguro
Journal:  Clin Exp Immunol       Date:  2015-04-23       Impact factor: 4.330

5.  Transmissible proteins: expanding the prion heresy.

Authors:  Claudio Soto
Journal:  Cell       Date:  2012-05-25       Impact factor: 41.582

6.  Genome-wide screen identifies curli amyloid fibril as a bacterial component promoting host neurodegeneration.

Authors:  Chenyin Wang; Chun Yin Lau; Fuqiang Ma; Chaogu Zheng
Journal:  Proc Natl Acad Sci U S A       Date:  2021-08-24       Impact factor: 11.205

Review 7.  The neuropathology of sport.

Authors:  Ann C McKee; Daniel H Daneshvar; Victor E Alvarez; Thor D Stein
Journal:  Acta Neuropathol       Date:  2013-12-24       Impact factor: 17.088

8.  The spectrum of disease in chronic traumatic encephalopathy.

Authors:  Ann C McKee; Robert A Stern; Christopher J Nowinski; Thor D Stein; Victor E Alvarez; Daniel H Daneshvar; Hyo-Soon Lee; Sydney M Wojtowicz; Garth Hall; Christine M Baugh; David O Riley; Caroline A Kubilus; Kerry A Cormier; Matthew A Jacobs; Brett R Martin; Carmela R Abraham; Tsuneya Ikezu; Robert Ross Reichard; Benjamin L Wolozin; Andrew E Budson; Lee E Goldstein; Neil W Kowall; Robert C Cantu
Journal:  Brain       Date:  2012-12-02       Impact factor: 13.501

9.  Extracellular environment modulates the formation and propagation of particular amyloid structures.

Authors:  Laura Westergard; Heather L True
Journal:  Mol Microbiol       Date:  2014-04-09       Impact factor: 3.501

Review 10.  Drosophila models of proteinopathies: the little fly that could.

Authors:  Diego E Rincon-Limas; Kurt Jensen; Pedro Fernandez-Funez
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.